Lapatinib Teva 250 mg filmom obložene tablete
| Name | Lapatinib Teva 250 mg filmom obložene tablete |
|---|---|
| Marketing Authorisation Number | HR-H-575193071 |
| Active Substance | lapatinibditosilat hidrat |
| Composition | jedna filmom obložena tableta sadrži lapatinibditosilat hidrat, što odgovara 250 mg lapatiniba |
| Pharmaceutical Form | Filmom obložena tableta |
| Manufacturer | Actavis Group PTC ehf., Hafnarfjoerdur, Island
Balkanpharma - Dupnitsa AD, Dupnitsa, Bugarska Actavis International Ltd., Luqa, Malta |
| Marketing Authorisation Holder | TEVA GmbH, Graf-Arco-Str. 3, Ulm, Njemačka |
| Marketing Authorisation Date | 17.08.2023 |
| MA Period of Validity | 17.08.2028 |
| Classification Number | UP/I-530-09/21-01/308 |
| Registration Number | 381-12-01/171-23-08 |
| Prescription | na recept |
| Type of prescription | ograničeni recept |
| Distribution | u ljekarni |
| Advertising to general public | zabranjeno |
| ATC Code | L01EH01 |
| SmPC | download |
| PL | download |
| Public Assessment Report | download |
| Summary of risk management plan | download |
